ObsEva
Earnings Call Transcript
OBSV Stock ,Investor Relations at ObsEva. Good morning or afternoon , to our listeners in across the US and Europe and welcome to our call today. Today’s call is along with Ernest Loumaye, our Co-Founder and Chief Executive Officer. Elizabeth Garner, our Chief Medical Officer; Wim Souverijns, our Chief Commercial Officer; Tim Adams, our Chief Financial Officer, and Jean-Pierre Gotteland the Chief Scientist.
During today’s call, ObsEva management will be making forward-looking statements, including but not limited to, statements relating to financial results and trends; the process and timing of anticipated future development of ObsEva’s product candidates, our oxytocin receptor antagonist, nolasiban; our gonadotropin-releasing hormone receptor antagonist, linzagolix; and our prostaglandin F2 alpha receptor antagonist, ObE022.
These forward-looking statements contain remarks about the expected results from clinical trials and regulatory pathways that exist in Europe, the US, Europe and Asia and the commercial and therapeutic potential for ObsEva’s product. These statements are based on the current expectations of ObsEva and are subject to significant uncertainties and risks. ObsEva’s actual performance and timing of events may differ significantly from what is anticipated in forward-looking statements. The risks and uncertainties could include, but are not limited to those relating to ObsEva’s programs for development clinical timelines for trials and outcomes, the uncertainty of the procedure for developing clinical products, including negative events and the successful costs and timings of all research and development activities during studies in clinical trial, potential for market for ObsEva’s candidate products and the accuracy of estimates made by ObsEva about capital requirements, expenses and the necessity for financing as well as other risks described within the Risk Factors as well as elsewhere in ObsEva’s filings to the US Securities and Exchange Commission and a 20-F report for the fiscal year ending on December 31, 2019 to be filed about March 5 2020, as well with other reports that are that are filed under Form 6-K and 20-F.
ObsEva is not under any obligation to revise any forward-looking statement as a result of any new information or future events, or any changes in expectations, other than as required by the law.
ObsEva Returns in a row. S&P
| 1 YEAR | 5 YEAR | 5 YEAR ANNUALIZED | SINCE IPO | |
|---|---|---|---|---|
| OBSV | -85.85% | -98.36% | -56.03% | -98% |
| S&P | -9.18% | +56.15% | +9.31% | +78% |
Assets
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Net Cash | $9.68M | -84.6% |
| Accounts Receivable | – | – |
| Inventory | 0 | – |
Liabilities
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Long Term Debt | $0.00M | – |
| Short Term Debt | $9.27M | +1,227.9% |
Ratios
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Return On Assets | -134.0% | +115.1% |
| Return On Invested Capital | -118.2% | +2.8% |
Cash Flow
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Free Cash Flow | -$5.09M | -71.1% |
| Operating Free Cash Flow | -$5.09M | -71.0% |
Valuation
QUARTERLYANNUAL
| Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | YOY CHANGE | |
|---|---|---|---|---|---|
| Price to Earnings | – | – | – | – | – |
| Price to Book | 3.51 | 3.49 | 4.82 | -5.71 | – |
| Price to Sales | – | – | – | – | – |
| Price to Tangible Book Value | 7.89 | 14.39 | 33.17 | -1.82 | – |
| Price to Free Cash Flow TTM | – | – | – | – | – |
| Enterprise Value to EBITDA | -7.07 | -7.86 | -8.51 | -3.13 | -72.0% |
| Free Cash Flow Yield | – | – | – | – | – |
| Return on Equity | -286.9% | -129.6% | -323.0% | -374.0% | +118.1% |
| Total Debt | $26.66M | $33.88M | $33.47M | $9.27M | -65.3% |
